Gilead Sciences, Inc.

Gilead Connecticut, Inc.

Genentech, Inc.

Cgi Pharmaceuticals, Inc.

Kronos Bio, Inc.

Genetech, Inc.

Jeffrey E Kropf

Kevin S Currie

Peter A Blomgren

Jianjun Xu

Scott A Mitchell

Seung H Lee

Zhongdong Zhao

Aaron C Schmitt

Jennifer R Lo

Douglas Gregory Stafford

Jin-Ming Xiong

Sundaramoorthi Swaminathan

Kirk L Stevens

Jayaraman Chandrasekhar

Pavel E Zhichkin

Christian Gege

Leena Patel

Christopher T Clark

Yasamin Moazami

Jason K Perry

Nicole Nava

Natalie Seeger

Taryn Campbell

Jennifer Anne Treiberg

Xiaojing Wang

Daniel Fred Ortwine

Wendy B Young

Suet Chung Yeung

Julian Andrew Codelli

Stephane Perreault

Julie Farand

Kassandra F Sedillo

Antonio J M Barbosa

William John Watkins

Honglu Zhang

Ravi Krishnamoorthy

David M Armistead

Antonio J M Barbosa, Jr

Soumya Mitra

James P Harding

Jeff A Zablocki

John O Link

Hyung-Jung Pyun

Chandrasekar Venkataramani

Scott E Lazerwith

Zheng-Yu Yang

Darryl Kato

Sheila M Zipfel

Gregory Notte

Juan A Guerrero

Jiayao Li

Adam James Schrier

Zhimin Du

Michael Sangi

Ashley Anne Katana

David R Brittelli

James William Darrow

Julie A Di Paolo

Astrid Clarke

Antonio J Barbosa

Nicholas Mai

James W Darrow

Joshua A Kaplan

Olaf Kinzel

Claus Kremoser

Douglas A Pippin

William Martin Rennells

Morin Mae Frick

Douglas A I Pippin

Elizabeth M Horstman

JinMing Xiong

Tony Lee

Steven L Gallion

Douglas G Stafford

Peter Blomgren

William M Rennells

Jinming Xiong

Jr Antonio J Barbosa

The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

FXR (NR1H4) modulating compounds

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2:

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Quinoline derivatives

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

Compounds for inhibition of &#x3b1;4 &#x3b2;7 integrin

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2: 

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Compounds for inhibition of alpha 4 beta 7 integrin

The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Compounds for inhibition of &#x3b1;4&#x3b2;7 integrin

Imidazopyridine derivatives

Certain imidazopyridines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Imidazopyridines Syk inhibitors

Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Growing community of inventors

Issaquah, WA, United States of America

Jeffrey E Kropf